First-line therapies and clinical responses
First-line . | n . | Clinical responses, n (%) . | |||
---|---|---|---|---|---|
CR . | PR . | SD . | Progression . | ||
IVIg | 20 | 4 (20) | 8 (40) | 6 (30) | 2 (10) |
Corticosteroids | 11 | 0 (0) | 1 (10) | 0 (0) | 10 (90) |
Chlorambucil | 3 | 0 (0) | 1 (33) | 0 (0) | 2 (67) |
Plasma exchange | 3 | 0 (0) | 2 (67) | 0 (0) | 1 (33) |
CHOP regimen | 2 | 0 (0) | 1 (50) | 0 (0) | 1 (50) |
Azathioprine | 1 | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
Rituximab | 1 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
Total | 41 | 4 (10) | 14 (34) | 7 (17) | 16 (39) |
First-line . | n . | Clinical responses, n (%) . | |||
---|---|---|---|---|---|
CR . | PR . | SD . | Progression . | ||
IVIg | 20 | 4 (20) | 8 (40) | 6 (30) | 2 (10) |
Corticosteroids | 11 | 0 (0) | 1 (10) | 0 (0) | 10 (90) |
Chlorambucil | 3 | 0 (0) | 1 (33) | 0 (0) | 2 (67) |
Plasma exchange | 3 | 0 (0) | 2 (67) | 0 (0) | 1 (33) |
CHOP regimen | 2 | 0 (0) | 1 (50) | 0 (0) | 1 (50) |
Azathioprine | 1 | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
Rituximab | 1 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
Total | 41 | 4 (10) | 14 (34) | 7 (17) | 16 (39) |